Changes in Beneficial Ownership · 4
Cosmos Health Inc.
COSMNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-05-19-05:00
- Issuer
- Cosmos Health Inc.
- Issuer CIK
- 0001474167
- Trading symbol
- COSM
Reporting owner 1
- Name
- Demetriades Demetrios G.
- Reporting owner CIK
- 0001989115
- Relationship
- Director · Officer
- Officer title
- Secretary
- Address
- 5 AG. GEORGIOU STR., PILEA, GREECE, THESSALONIKI, J3, TK57001
Non-derivative transactions
| Security | Transaction date | Deemed execution | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.001 | 2026-05-19-05:00 | 2026-05-19-05:00 | A · Form 4[F1] | 20,000 | A | 0.2830 | 55,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Deemed execution | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Unit | [F2] | 2026-05-19-05:00 | 2026-05-19-05:00 | C · Form 4 | 20,000 | D | 0 | 2026-05-19 | 2036-05-19 | Common Stock, par value $.001 | 20,000 | 0 | D |
Table key
- C · Form 4
- Derivative conversion
- D
- Direct
Footnotes
- F1
- Reflects the award of 20,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3.↩ 1
- F2
- The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.↩ 1
Signature 1
- Signed
- /s/ Demetrios G. Demetriades
- Date
- 2026-06-11
Company context
Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is avai